Bio-sample
|
Genotype
|
Storage format
|
---|
Genetic modification in prostate
| | |
Prostatea
|
Pten
−
/−
|
Frozen + paraffin
|
Lung
|
Pten
+
/+
|
Frozen + paraffin
|
Bladder
|
Pten
+
/+
|
Frozen
|
Thyroid
|
Pten
+
/+
|
Frozen
|
Spleen
|
Pten
+
/+
|
Frozen
|
Whole blood
|
Pten
+
/+
|
Frozen
|
Serum
|
Pten
+
/+
|
Frozen
|
Genetic modification in lung
| | |
Prostate
|
Pten
+
/+
|
Frozen + paraffin
|
Lungb
|
Pten
−
/−
|
Frozen + paraffin
|
Bladder
|
Pten
+
/+
|
Frozen
|
Thyroid
|
Pten
+
/+
|
Frozen
|
Spleen
|
Pten
+
/+
|
Frozen
|
Whole blood
|
Pten
+
/+
|
Frozen
|
Serum
|
Pten
−
/−
|
Frozen
|
- All mice were intranasally-instilled, 3 doses (4 mg) every other day. Time to harvest was 1–6 months post-final exposure in mice with genetically-modified prostates, and > 4 months post-final exposure in mice with genetically-modified lung tissue
- a Pb-Cre+; PtenLL GEM model
- b Mice treated with (1) WTC dust, (2) PBS, (3) WTC dust + Ad-cre, or (4) PBS + Ad-cre